According to a new report published by Allied Market Research, titled, “HIV Injection Market," The HIV injection market was valued at $1 billion in 2023, and is estimated to reach $5.5 billion by 2033, growing at a CAGR of 17.9% from 2024 to 2033. North America dominated the market in 2023 owing to the availability of approved products, well-established healthcare system, and is anticipated to grow at a CAGR of 17.6% during the forecast period.
Request Sample of the Report on HIV Injection Market Forecast 2033 https://www.alliedmarketresearch.com/request-sample/A312373
The growth of the HIV injection market is fueled by an increasing number of individuals afflicted with HIV, heightened awareness concerning early detection and treatment, and a surge in research and development endeavors. Notably, as per the World Health Organization (WHO) report from July 2023, HIV continues to pose a significant global public health challenge, with advanced HIV disease persisting as a substantial issue in the HIV response. According to the same source, by the end of 2022, there were approximately 39.0 million people living with HIV, with about 1.3 million individuals contracting the virus in 2022.
In 2023, North America emerged as the dominant force in the global HIV injection market, with a significant market share. This can be attributed to several factors, including the availability of approved HIV injection treatments, a well-established healthcare infrastructure that prioritizes early diagnosis and treatment accessibility, and comprehensive HIV care programs. These elements collectively contribute to the heightened demand for HIV injection therapies in the region.
Furthermore, North America benefits from the strong presence of key industry players and a growing adoption of strategic initiatives such as product approvals, which further propel market growth.
On the other hand, the Asia-Pacific region is poised to exhibit the highest compound annual growth rate (CAGR) throughout the forecast period in the HIV injection industry. This projection is primarily driven by factors such as a growing target population, increasing unmet medical needs, a rise in healthcare expenditure, and a surge in HIV cases within the region.
Recent Developments in the HIV Injection Industry
- In October 2023, ViiV Healthcare, the global specialist HIV company with majority owned by GSK announced that the National Medical Products Administration (NMPA) of China approved Vocabria (cabotegravir injection) used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.
- In September 2023, ViiV Healthcare, the global specialist HIV company with majority owned by GSK, announced that the European Commission has authorised Apretude (cabotegravir long-acting (LA) injectable and tablets) for HIV prevention.
- In February 2023, Gilead Sciences, Inc. announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing.Results fromthe Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV.
- In January 2022, ImmunityBio, Inc., a clinical-stage immunotherapy company announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer (NK) cells in people living with HIV by ImmunityBio’s IL-15 superagonist Anktiva (N-803). Anktiva stimulates latent HIV replication (the “kick”) in CD4 memory cells allowing the previously hidden infected cells to be revealed and eliminated (the “kill”) by CD8 and NK cells.
Inquiry Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/A312373
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv injection market analysis from 2023 to 2033 to identify the prevailing hiv injection market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the hiv injection market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global hiv injection market trends, key players, market segments, application areas, and market growth strategies.
Key Findings of the Study
- By distribution channel, the others segment dominated the HIV injection market size in 2023.
- Region-wise, North America held the largest HIV injection market size in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
- India is expected to grow at a significant CAGR of 22.7% during the forecast period.
- In Europe, Germany held the largest share in the HIV injection market in 2023.
- Brazil is anticipated to grow at a significant CAGR of 21.5% during the forecast period.
Leading Market Players
- GlaxoSmithKline plc
- Johnson and Johnson
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F. Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie Inc.
- Brii Biosciences
- Shionogi and Co., Ltd.
Related Reports :
No comments:
Post a Comment